Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
| ▸ | CASP2 | P42575 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | F13A1 | P00488 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25444826 | 0.98 | CHRM2 (0.52) | CHRM2TDP1PRMT3CARM1PRMT6 | |
| SCHEMBL23191048 | 0.93 | CHRM2 (0.58) | CHRM2TDP1PRMT3CARM1PRMT6 | |
| SCHEMBL4021737 | 0.91 | CHRM2 (0.54) | CHRM2TDP1PRMT3CARM1PRMT6 | |
| SCHEMBL6687880 | 0.91 | CHRM2 (0.48) | CHRM2TDP1PRMT3CARM1PRMT6 | |
| SCHEMBL1231390 | 0.87 | PRMT3 (0.50) | CHRM2TDP1PRMT3CARM1PRMT6 | |
| SCHEMBL812040 | 0.86 | CHRM2 (0.50) | CHRM2TDP1PRMT3CARM1PRMT6 | |
| SCHEMBL10045279 | 0.85 | PRMT3 (0.48) | CHRM2TDP1PRMT3CARM1PRMT6 | |
| SCHEMBL469832 | 0.85 | PRMT3 (0.48) | CHRM2TDP1PRMT3CARM1PRMT6 | |
| SCHEMBL16317337 | 0.85 | PRMT3 (0.48) | CHRM2TDP1PRMT3CARM1PRMT6 | |
| Hydrochloric Acid SCHEMBL15775227 | 0.85 | PRMT3 (0.48) | CHRM2TDP1PRMT3CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3512865-B1 | ESTERS OF 3-POLYAMINE DERIVATIVES OF BILE ACIDS FOR THE TREATMENT OF INFECTIONS | VIRBAC (FR) | 2021-05-05 | — | — | EP | disclosed |
| EP-3512864-B1 | AMIDE DERIVATIVES OF SQUALAMINE FOR THE TREATMENT OF INFECTIONS | VIRBAC (FR) | 2021-01-20 | — | — | EP | disclosed |
| US-10780101-B2 | Amide derivatives of squalamine for the treatment of infections | VIRBAC (FR) | 2020-09-22 | — | — | US | disclosed |
| EP-3134409-B1 | COMPOUNDS AND USE THEREOF IN THE EXPANSION OF HEMATOPOIETIC STEM CELLS AND/OR HEMATOPOIETIC PROGENITOR CELLS | UNIV MONTREAL (CA) | 2020-02-12 | — | — | EP | disclosed |
| US-20190262362-A1 | AMIDE DERIVATIVES OF SQUALAMINE FOR THE TREATMENT OF INFECTIONS | VIRBAC (FR) | 2019-08-29 | — | — | US | disclosed |
| US-20190255073-A1 | ESTERS OF 3-POLYAMINE DERIVATIVES OF BILE ACIDS FOR THE TREATMENT OF INFECTIONS | VIRBAC (FR) | 2019-08-22 | — | — | US | disclosed |
| US-10023697-B2 | Condensation polymers for antimicrobial applications | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023697-B2 | Condensation polymers for antimicrobial applications | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2018-07-17 | — | — | US | disclosed |
| WO-2018050815-A1 | AMIDE DERIVATIVES OF SQUALAMINE FOR THE TREATMENT OF INFECTIONS | VIRBAC (FR) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018050814-A1 | ESTERS OF 3-POLYAMINE DERIVATIVES OF BILE ACIDS FOR THE TREATMENT OF INFECTIONS | VIRBAC (FR) | 2018-03-22 | — | — | WO | disclosed |
| EP-1322568-A1 | SIZING COMPOSITION FOR GLASS YARNS, METHOD USING SAID COMPOSITION AND RESULTING PRODUCTS | Saint-Gobain Vetrotex France S.A. (FR) | 2003-07-02 | — | — | EP | disclosed |
| WO-2003048066-A1 | SIZING COMPOSITION FOR GLASS YARNS, THE GLASS YARNS THUS OBTAINED AND COMPOSITE MATERIALS COMPRISING SAID YARNS | SAINT-GOBAIN VETROTEX FRANCE S.A. (FR) | 2003-06-12 | — | — | WO | disclosed |
| US-6514612-B1 | Polymerization and crosslinking of acrylate and amine functionalized compounds and/or polymers; reinforcement composites | VETROTEX FRANCE (FR) | 2003-02-04 | — | — | US | disclosed |
| WO-2001087792-A1 | SIZING COMPOSITION FOR GLASS YARNS, METHOD USING SAID COMPOSITION AND RESULTING PRODUCTS | SAINT-GOBAIN VETROTEX FRANCE S.A. (FR) | 2001-11-22 | — | — | WO | disclosed |
| EP-1042248-A1 | GLASS FIBRE COATING COMPOSITION, METHOD USING SAID COMPOSITION AND RESULTING PRODUCT | VETROTEX FRANCE (FR) | 2000-10-11 | — | — | EP | disclosed |
| EP-0813505-B1 | GLASS YARN SIZING COMPOSITION, METHOD USING SAME AND RESULTING PRODUCTS | VETROTEX FRANCE SA (FR) | 2000-05-17 | — | — | EP | disclosed |
| US-5961684-A | Sizing composition for glass strands, process using this composition and resulting products | VETROTEX FRANCE (FR) | 1999-10-05 | — | — | US | disclosed |
| WO-1999031025-A1 | GLASS FIBRE COATING COMPOSITION, METHOD USING SAID COMPOSITION AND RESULTING PRODUCT | VETROTEX FRANCE (FR) | 1999-06-24 | — | — | WO | disclosed |
| EP-0813505-A1 | GLASS YARN SIZING COMPOSITION, METHOD USING SAME AND RESULTING PRODUCTS | VETROTEX FRANCE S.A. (FR) | 1997-12-29 | — | — | EP | disclosed |
| WO-1997025288-A1 | GLASS YARN SIZING COMPOSITION, METHOD USING SAME AND RESULTING PRODUCTS | VETROTEX FRANCE (FR) | 1997-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262362-A1 | AMIDE DERIVATIVES OF SQUALAMINE FOR THE TREATMENT OF INFECTIONS | SUCNR1, GLRA1, SRR | CHRM2 1731/4885TDP1 3901/4885PRMT3 497/4885 |
| US-10023697-B2 | Condensation polymers for antimicrobial applications | PUF60, PARG, PARN | CHRM2 4586/4885TDP1 2628/4885PRMT3 1412/4885 |
| US-20190255073-A1 | ESTERS OF 3-POLYAMINE DERIVATIVES OF BILE ACIDS FOR THE TREATMENT OF INFECTIONS | GPBAR1, NR1H4, ESRRA | CHRM2 2921/4885TDP1 3769/4885PRMT3 165/4885 |
| US-10780101-B2 | Amide derivatives of squalamine for the treatment of infections | SUCNR1, GLRA1, SRR | CHRM2 1731/4885TDP1 3901/4885PRMT3 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.